Home » Stocks » INMB

Inmune Bio Inc. (INMB)

Stock Price: $20.72 USD -4.40 (-17.52%)
Updated Jan 21, 2021 12:57 PM EST - Market open
Market Cap 337.81M
Revenue (ttm) n/a
Net Income (ttm) -11.21M
Shares Out 12.93M
EPS (ttm) -0.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $20.72
Previous Close $25.12
Change ($) -4.40
Change (%) -17.52%
Day's Open 28.80
Day's Range 19.88 - 29.99
Day's Volume 2,118,913
52-Week Range 2.21 - 29.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 hours ago

Interim data show CSF biomarkers of neurodegeneration and synaptic dysfunction as well as neuroimaging biomarkers improved after three months of therapy with XPro1595

GlobeNewsWire - 1 week ago

Webinar to review expanded biomarker data from the company's Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer's disease

Insider Monkey - 1 month ago

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...

Insider Monkey - 2 months ago

In this article we present the list of Top 10 Stocks Billionaire George Soros Just Bought. Click to skip ahead and see the  Top 5 Stocks Billionaire George Soros Just Bought .

Other stocks mentioned: DIS, MCHP, MXIM, NGHC, NXPI, PLTR, PPG, U, VAR
GlobeNewsWire - 2 months ago

LA JOLLA, Calif, Nov. 09, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patie...

Seeking Alpha - 2 months ago

INmune Bio, Inc. (INMB) CEO RJ Tesi on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Management to host conference call at 4:30 pm ET on that day

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the pati...

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness ...

GlobeNewsWire - 4 months ago

100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant disease

GlobeNewsWire - 4 months ago

LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the p...

GlobeNewsWire - 5 months ago

LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the pa...

Seeking Alpha - 5 months ago

INmune Bio Inc. (INMB) CEO RJ Tesi on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

The company will host an earnings call: Today, August 5 at 4:30 PM ET The company will host an earnings call: Today, August 5 at 4:30 PM ET

GlobeNewsWire - 5 months ago

LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that ha...

GlobeNewsWire - 5 months ago

LA JOLLA, Calif, July 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the pa...

GlobeNewsWire - 6 months ago

LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, July 20th by INmune Bio, Inc. (NASDAQ: INMB) was incorrectly reported with below se...

GlobeNewsWire - 6 months ago

LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that har...

GlobeNewsWire - 6 months ago

LA JOLLA, Calif, July 16, 2020 (GLOBE NEWSWIRE) --   INmune Bio, Inc.  (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that...

Seeking Alpha - 6 months ago

INmune Bio: Stronger Support From Alzheimer's Drug XPro1595

GlobeNewsWire - 6 months ago

LA JOLLA, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments th...

InvestorPlace - 6 months ago

Inmune Bio (INMB) stock is taking off on Tuesday after announcing positive Alzheimer's news for its leading drug candidate XPro1595.

Investors Business Daily - 6 months ago

Inmune Bio stock skyrocketed to a record high Tuesday after the biotech company unveiled promising results for its Alzheimer's treatment. The drug targets inflammation in the brain.

Benzinga - 6 months ago

Micro-cap biotech INmune Bio Inc (NASDAQ: INMB) is advancing strongly Tuesday following a positive clinical readout from the company.

GlobeNewsWire - 6 months ago

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learni...

GlobeNewsWire - 7 months ago

Study will be the first-in man trial for INKmune – a novel therapy to prime the patient’s own NK cells to attack their cancer

GlobeNewsWire - 8 months ago

Review highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of cancer

Seeking Alpha - 8 months ago

INmune Bio Inc. (INMB) CEO RJ Tesi on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

The company will host an earnings call: Today, May 14 at 4:30 PM ET The company will host an earnings call: Today, May 14 at 4:30 PM ET

GlobeNewsWire - 8 months ago

LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate i...

GlobeNewsWire - 9 months ago

Conference call at 4:15 PM ET with management to discuss the science and strategy of clinical trial to determine if  the Company’s DN-TNF platform could be used to treat catastrophic compli...

Seeking Alpha - 10 months ago

INmune Bio Inc. (INMB) CEO R.J.

GlobeNewsWire - 11 months ago

Grant will fund proof-of-concept studies for XPro1595 therapy

GlobeNewsWire - 1 year ago

Dr. Malú Tansey's peer-reviewed data from INmune Bio's lead compound XPro1595 published in Alzheimer's Research & Therapy Dr. Malú Tansey's peer-reviewed data from INmune Bio's lead compound X...

GlobeNewsWire - 1 year ago

Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer

About INMB

INmune Bio, a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 2019
CEO
Dr. Raymond Joseph Tesi
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
INMB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Inmune Bio stock is "Buy." The 12-month stock price forecast is 20.00, which is a decrease of -3.47% from the latest price.

Price Target
$20.00
(-3.47% downside)
Analyst Consensus: Buy